Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KALVNASDAQ:KINNASDAQ:OPTNOTCMKTS:PFSCFNASDAQ:ZYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$11.86+7.1%$13.56$6.83▼$16.88$500.37M0.9556,876 shs2.15 million shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsOPTNOptiNose$1.46-1.4%$1.53$0.90▼$2.10$164.47M-0.211.00 million shs399,574 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AZYNEZynerba Pharmaceuticals$1.30+2.4%$1.30$0.25▼$1.40$70.12M1.32515,333 shs862,700 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals+7.14%-2.39%-18.88%-3.18%+59.19%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%OPTNOptiNose-1.35%-12.05%-13.61%+13.18%-25.51%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%+195.45%Grab Your Free Bitcoin Today! (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALVKalVista Pharmaceuticals3.9794 of 5 stars3.51.00.04.51.92.50.6KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AOPTNOptiNose4.5928 of 5 stars3.53.00.04.23.82.50.6PFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALVKalVista Pharmaceuticals3.00Buy$26.33122.03% UpsideKINKindred BiosciencesN/AN/AN/AN/AOPTNOptiNose3.00Buy$4.00173.97% UpsidePFSCFProMetic Life SciencesN/AN/AN/AN/AZYNEZynerba Pharmaceuticals2.25Hold$1.11-14.62% DownsideCurrent Analyst RatingsLatest PFSCF, KIN, OPTN, ZYNE, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.002/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALVKalVista PharmaceuticalsN/AN/AN/AN/A$2.10 per shareN/AKINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29OPTNOptiNose$70.99M2.32N/AN/A($0.77) per share-1.90PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AOPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/AZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest PFSCF, KIN, OPTN, ZYNE, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALVKalVista PharmaceuticalsN/A5.445.44KINKindred Biosciences0.197.027.02OPTNOptiNoseN/A0.600.55PFSCFProMetic Life SciencesN/A0.950.71ZYNEZynerba PharmaceuticalsN/A3.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALVKalVista PharmaceuticalsN/AKINKindred Biosciences66.89%OPTNOptiNose85.60%PFSCFProMetic Life Sciences0.10%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipKALVKalVista Pharmaceuticals12.30%KINKindred Biosciences13.69%OPTNOptiNose2.20%PFSCFProMetic Life SciencesN/AZYNEZynerba Pharmaceuticals13.04%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableOPTNOptiNose132112.65 million110.17 millionNot OptionablePFSCFProMetic Life Sciences48723.31 millionN/ANot OptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionablePFSCF, KIN, OPTN, ZYNE, and KALV HeadlinesSourceHeadlineHarmony Biosciences Reports Strong Third Quarter 2023 Financial Resultsfinance.yahoo.com - October 31 at 7:57 AMWhy Shares of Harmony Bioscience Are Falling on Fridayfool.com - October 13 at 12:59 PMNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapiesmarkets.businessinsider.com - October 11 at 9:47 AMHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEfinance.yahoo.com - October 11 at 9:47 AMH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 10 at 1:59 PMAnalysts: ZYNE stock price target of $1.25 in 12 monthsknoxdaily.com - October 5 at 6:47 PMImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructionsfinance.yahoo.com - October 4 at 7:33 PMExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 2 at 3:14 PM20 Countries With Highest Rate of Epilepsyfinance.yahoo.com - September 29 at 6:24 PMZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023finance.yahoo.com - September 29 at 1:23 PMHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealbizjournals.com - September 27 at 2:42 PMZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Riseknoxdaily.com - September 25 at 8:15 PMZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwrightknoxdaily.com - September 20 at 12:12 PMNegative sentiment towards ZYNE reflected in surge in short interestknoxdaily.com - September 15 at 8:27 PMInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Incfinance.yahoo.com - September 14 at 11:23 PMZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposiumfinance.yahoo.com - September 14 at 6:23 PMZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statementlaw.com - September 11 at 4:04 PMPositive sentiment towards ZYNE reflected in decline in short interestknoxdaily.com - September 8 at 5:19 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRbakersfield.com - August 31 at 5:00 PMHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)msn.com - August 16 at 4:20 AMHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyoutbiospace.com - August 15 at 6:19 PMZynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?dhakatribune.com - August 15 at 6:19 PMIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 15 at 6:19 PMZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEmarketwatch.com - August 14 at 9:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesYour Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank Stocks5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit Upside3 Cheap Stocks That Shouldn’t Be Cheap for Long March 26, 2024 9:49 AMView 3 Cheap Stocks That Shouldn’t Be Cheap for Long 4 Oversold Large Cap Stocks Yielding High DividendsMarch 14, 2024 6:30 AMView 4 Oversold Large Cap Stocks Yielding High DividendsActive Rebound: 2 Discrete Semiconductor Stocks Making MovesMarch 12, 2024 8:00 AMView Active Rebound: 2 Discrete Semiconductor Stocks Making MovesAll Headlines Company DescriptionsKalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Kindred BiosciencesNASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.ProMetic Life SciencesOTCMKTS:PFSCFPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Zynerba PharmaceuticalsNASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.